What your support has discovered.
- 21
- milestone papers
- 20
- years of research
- 81%
- of gifts to research
Milestones by year
2006 One milestone
Experimental Neurology
Your earliest support funded the discovery that started it all: BMAA, a toxin produced by cyanobacteria (blue-green algae), directly injures motor neurons. This was the first hard evidence connecting an environmental toxin to the disease process behind ALS.
Experimental Neurology, 201: 244–252
2008 One milestone
Environmental Microbiology
Follow-up research found the same toxin in reservoirs across the UK, providing evidence for much greater environmental exposure than previously thought.
Environmental Microbiology, 10(3): 702–708
2009 One milestone
Amyotrophic Lateral Sclerosis
Your support helped establish the link between BMAA exposure and elevated ALS rates in Gulf War veterans, one of the clearest human populations pointing to an environmental trigger.
Amyotrophic Lateral Sclerosis, 10 (Suppl 2): 109–117
2013 One milestone
PLOS ONE
A pivotal discovery: BMAA can mistakenly be built into human proteins leading to cell death, which can be prevented by L-serine.
PLOS ONE, 8(9): e75376
2016 Two milestones
Proceedings of the Royal Society B · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Your support helped show BMAA can trigger the same brain changes seen in Alzheimer's disease, extending the toxin's reach beyond ALS.
Proceedings of the Royal Society B, 283: 20152397Building on that discovery, we launched a Phase I clinical trial testing L-serine in ALS patients. L-serine supplementation slowed ALS disease progression by up to 85%, marking the first evidence that L-serine might be an effective therapy to treat ALS.
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
2019 One milestone
PLOS ONE
Stranded dolphins in Florida were the first animals found with detectable BMAA in their brains alongside Alzheimer's- and ALS-like brain damage, providing a direct link between BMAA and neurodegenerative diseases.
PLOS ONE: Cyanobacterial neurotoxin BMAA and brain pathology in stranded dolphins
2020 Two milestones
Journal of Neuropathology and Experimental Neurology · Open Biology
L-serine was shown to reduce ALS symptoms in an animal model, and BMAA was shown to trigger those same symptoms, closing the loop between cause and possible treatment.
Journal of Neuropathology and Experimental Neurology, nlaa002Your support helped identify eight distinct blood markers that reliably tell ALS patients apart from healthy people using a simple blood draw. This is the first step towards a rapid and accurate ALS biomarker test.
Open Biology, 10: 200116
2021 One milestone
Neurotoxicity Research
Your funding helped establish the link between algal bloom toxins and human and animal brain disease, building the case that ALS may be preventable, not just treatable.
Neurotoxicity Research, 39: 27–35
2022 Four milestones
Journal of the Neurological Sciences · PLOS ONE · Phase II clinical trial · Journal of Natural Products
The high sensitivity of the ALS blood biomarker held up in a larger and more diverse group of participants, bringing this innovation one step closer to helping patients.
Journal of the Neurological Sciences, 442: 120396The same research approach advancing our ALS biomarker test showed promise for Alzheimer's too, pointing to a possible blood test for earlier detection.
PLOS ONE, 17(4): e0267407Establishment of L-serine as a neuroprotective molecule led us to initiate a Phase II clinical trial testing L-serine in patients with Mild Cognitive Impairment at Houston Methodist Hospital. This is true translational research, moving L-serine from the bench to the bedside. Trial results should be available in 2027.
Phase II clinical trial, Houston Methodist Hospital
Cyclotides, a class of plant peptides found in violets, showed early promise as a partner therapy for one of the deadliest brain cancers, glioblastoma. This promising new avenue of research provides hope for patients where few effective therapies exist.
Journal of Natural Products, 85(1): 34–46
2023 Two milestones
Toxins · Toxicology Reports
Your support helped detect BMAA in the air itself around the Great Salt Lake, not just the water, raising new questions about how people are exposed.
Toxins, 15(11): 659BMAA was identified in the nasal pathways of Alzheimer's patients, reinforcing contaminated air as a risk factor and identifying a route for exposure that gives direct access to the brain.
Toxicology Reports, 10: 87–96
2024 Two milestones
Biomedicines · Brain Communications
Follow-up research confirmed cyclotides' potential to strengthen glioblastoma treatment, each study building the case for a therapy patients sorely need.
Biomedicines, 12(10): 2216With more data behind it, the ALS biomarker test moved closer to a stage where doctors can use it as a complementary tool to aid in diagnoses.
Brain Communications, 6(5): fcae268
2025 Two milestones
Communications Biology · Molecular Neurobiology
Stranded dolphins in Florida showed brain changes strikingly similar to Alzheimer's, providing more evidence that environmental neurotoxins don't stop at humans.
Communications Biology, 8: 1400With a single blood draw, your support helped deliver a rapid test that identifies ALS.
Molecular Neurobiology, 63: 298 (2026)
2026 One milestone
Toxins
New research shows BMAA can travel through the air, far from any lake or reservoir, reshaping how we think about prevention and why this work can't stop now.
Toxins, 18(7): 309
Getting the ALS test to patients
We are moving forward with getting our ALS test into the hands of patients. It has been validated in a commercial laboratory as a CLIA/CAP laboratory-developed test.
Fund this workTests for the diseases nobody is testing for
We are working to expand our biomarker tests to other underserved neurodegenerative diseases like Alzheimer's, Parkinson's, PLS (Primary Lateral Sclerosis), frontotemporal dementia and others. You can join us in achieving this goal.
Give onlineOur scientists are constrained by research funding, not capacity.
As a not-for-profit organization, we care only for patients, not profits.
Our innovative approach is working, but we need your support. Based on our 2025 audit, 81% of all gifts go to medical research.
